Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Jiangbo Predicts $8-$12 Million First Year Sales of Hypertension Drug

publication date: Aug 17, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Jiangbo Pharmaceuticals has received approval from the Shandong Food and Drug Administration to start selling a treatment for high blood pressure, Felodipine sustained release tablets. The company expects to sell $8 million to $12 million of the drug in the first 12 months at a 70% gross margin. More details...

Stock Symbol: (NSDQ: JGBO)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners